Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ: VTRS )

9.240 -0.100 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,026,060
Open 9.310
Bid (Size) 9.250 (1)
Ask (Size) 9.330 (3)
Prev. Close 9.340
Today's Range 9.230 - 9.470
52wk Range 8.770 - 13.55
Shares Outstanding 1,212,301,241
Dividend Yield 5.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire

Performance

YTD
-25.60%
-25.60%
1 Month
-12.99%
-12.99%
3 Month
-27.53%
-27.53%
6 Month
-18.52%
-18.52%
1 Year
-23.38%
-23.38%

More News

Read More
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Forecasting The Future: 4 Analyst Projections For Viatris
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
1 Healthcare Stock to Target This Week and 2 to Turn Down
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
From Faruqi & Faruqi LLP
Via GlobeNewswire
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session.
Via Chartmill
Tesla, Palantir And MicroStrategy Are Among Top 12 Large-Cap Losers Last Week (Feb 24-Feb 28): Are The Others In Your Portfolio?
Via Benzinga
Stay informed with the top movers within the S&P500 index on Thursday.
Via Chartmill
Why Viatris (VTRS) Shares Are Falling Today
Via StockStory
What's going on in today's session: S&P500 most active stocks
Via Chartmill
Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook
Via Benzinga
Topics Earnings
Exposures Financial Product Safety
Discover which S&P500 stocks are making waves on Thursday.
Via Chartmill
Gapping S&P500 stocks in Thursday's session
Via Chartmill
Viatris Misses Estimates, Cash Flow Up
Via The Motley Fool
Get insights into the top movers in the S&P500 index of Thursday's pre-market session.
Via Chartmill
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Via StockStory
Viatris (NASDAQ:VTRS) Misses Q4 Revenue Estimates, Stock Drops
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Viatris Earnings: What To Look For From VTRS
Via StockStory
Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
3 Reasons to Sell VTRS and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.